Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;19(6):311-8.
doi: 10.2188/jea.je20090039. Epub 2009 Oct 3.

Model of life expectancy of chronic hepatitis B carriers in an endemic region

Tao Wang  1
Affiliations

Model of life expectancy of chronic hepatitis B carriers in an endemic region

Tao Wang. J Epidemiol. 2009.

Abstract

Background: Chronic infection with hepatitis B (HBV) is a known risk factor for increased mortality from hepatocellular carcinoma (HCC) and chronic liver disease (CLD). However, the specific effects of chronic HBV infection on life expectancy have not been adequately studied. Taiwan is endemic for HBV infection, and thus provides sufficient information for such estimates.

Methods: Population mortality statistics, combined with data on the contribution of HBV to HCC and CLD deaths, were used to model carrier mortality by sex and e antigen status. An abridged life table was used to calculate carrier life expectancy.

Results: Among both males and females, those who are e antigen-positive are more likely to die from HCC than from CLD. When e antigen status remains positive, absolute liver mortality rates climb significantly after age 40 years. CLD is a proportionally higher threat for e antigen-negative females than for other subgroups. Males have higher liver-related mortality at all ages. A small decrease in life expectancy, from 82.0 to 80.1 years, was found for female noncarriers versus female carriers; a larger discrepancy was observed for males-from 76.2 to 71.8 years. In comparison to noncarriers, the lifetime relative risk of mortality is 1.35 for male carriers and 1.16 for female carriers.

Conclusions: These results indicate that chronic HBV infection results in significant liver-related mortality; however, carriers retain a satisfactory life expectancy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. The prevalence of hepatitis B e antigen by age, based on data from 2 seroprevalence surveys., The data were curve fitted with Curve Expert using the Levenberg-Marquardt method., The equation of the curve is displayed; the correlation coefficient was 0.998.
Figure 2.
Figure 2.. Age-specific mortality among male hepatitis B carriers caused by hepatocellular carcinoma and chronic liver disease, by e antigen status.
Figure 3.
Figure 3.. Age specific mortality among female hepatitis B carriers caused by hepatocellular carcinoma and chronic liver disease, by e antigen status.
Figure 4.
Figure 4.. Overall liver-related age-specific mortality of hepatitis B carriers, by sex.
Figure 5.
Figure 5.. Survival of hepatitis B carriers versus noncarriers, by sex.
See this image and copyright information in PMC

References

    1. Lee WM Hepatitis B virus infection . N Engl J Med. 1997;337:1733–45 10.1056/NEJM199712113372406 - DOI - PubMed
    1. Beasley RP Hepatitis B virus: the major etiology of hepatocellular carcinoma . Cancer. 1988;61:1942–56 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J - DOI - PubMed
    1. McMahon BJ , Alward WL , Hall DB , Heyward WL , Bender TR , Francis DP , et al. . Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state . J Infect Dis. 1985;151:599–603 - PubMed
    1. Chang MH Natural history of hepatitis B virus infection in children . J Gastroenterol Hepatol. 2000;15(5Suppl 1):E16–9 10.1046/j.1440-1746.2000.02096.x - DOI - PubMed
    1. Chu CM Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma . J Gastroenterol Hepatol. 2000;15(5suppl 1):E25–30 10.1046/j.1440-1746.2000.02097.x - DOI - PubMed

MeSH terms

Substances